Quality of Life and Health Care Utilization in the CIRCA-DOSE Study
| Autor: | Atul Verma, Paul Khairy, Laurent Macle, Anthony Tang, Circa-Dose Study Investigators, Peter Leong-Sit, Clarence Khoo, Jacques Rizkallah, Paul Novak, Jason G. Andrade, Jean-Francois Roux, Jean Champagne, Marc Dubuc, Sylvie Levesque, John L. Sapp, Marc W. Deyell |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Radiofrequency ablation medicine.medical_treatment Catheter ablation 030204 cardiovascular system & hematology Cardioversion Cryosurgery law.invention 03 medical and health sciences 0302 clinical medicine Quality of life Interquartile range law Atrial Fibrillation medicine Humans 030212 general & internal medicine business.industry Atrial fibrillation Patient Acceptance of Health Care medicine.disease Ablation Treatment Outcome Pulmonary Veins Emergency medicine Quality of Life Cardioversions business |
| Zdroj: | JACC. Clinical electrophysiology. 6(8) |
| ISSN: | 2405-5018 0191-3522 |
| Popis: | This study evaluated the impact of contact force-guided radiofrequency ablation versus cryoballoon ablation on quality of life and health care utilization.Traditional outcome parameters, such as arrhythmia-free survival, are insufficient to evaluate the clinical impact of atrial fibrillation (AF), as it fails to the capture patient- and health system-level differences in treatment approaches.The CIRCA-DOSE (Cryoballoon Vs. Contact-Force Atrial Fibrillation Ablation) study randomly assigned 346 patients with drug-refractory paroxysmal AF to contact force-guided radiofrequency or cryoballoon ablation. Health-related quality-of-life (HRQOL) was assessed at baseline, and at 6 and 12 months post-ablation using a disease-specific and generic HRQOL instruments. Health care utilization (hospitalization, emergency department visits, and cardioversion) and antiarrhythmic drug use for the 12 months preceding ablation was compared with the 12 months following ablation.Disease-specific and generic HRQOL was moderately to severely impaired at baseline and improved significantly at 6 and 12 months of follow-up (median improvement in AFEQT [Atrial Fibrillation Effect on QualiTy of Life] score 32.4 [interquartile range: 17.7 to 48.9]). When compared with the 12 months pre-ablation, the proportion and absolute number of cardioversions decreased significantly (41.1% vs. 10.1% of patients, 137 vs. 35 events; p 0.0001). Similar significant reductions in emergency department visits (66.7% vs. 25.1% of patients, 224 vs. 87 events; p 0.0001), and hospitalizations (25.5% vs. 14.5% of patients, 86 vs. 50 events; p 0.001) were observed. There were no significant differences between randomized groups.In this multicenter randomized trial, catheter ablation with advanced-generation technologies resulted in a significant improvement in HRQOL and a significant reduction in health care utilization in the year following AF ablation. (Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation [CIRCA-DOSE]; NCT01913522). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|